Cohort, COVID-19, Fibrosis, Follow-up, Sequelae, Spirometry DLCO
Conditions
Keywords
COVID-19, Fibrosis, cohort, follow-up, Sequelae, spirometry DLCO
Brief summary
As the investigators need data on long term outcome of Covid-19, especially respiratory sequelae, a national cohort is required. To better evaluate the potential respiratory sequelae after SARS-CoV-2 infection, it is fundamental to include patients with different management at the acute phase of the Covid-19: ambulatory management, hospitalization in non ICU and in ICU units. That is why the investigators will conduct a national cohort study with all components of french pneumology which will give the investigators the opportunity to include patients in general hospital, in university hospital and in private structure. As it is a real life study, the investigators will include all patients who will have a consultation with a pneumologist for an evaluation 5 to 7 months after a Covid-19 infection whatever their acute disease management. The investigators will collect all available data on Covid-19 acute phase, on patients characteristics and comorbidities, on persistent symptoms after Covid-19, on exams results during the outcome evaluation (CT-scan, 6 min walk test, spirometry and DLCO, blood gas, VO2 max if realized).
Interventions
None listed
Sponsors
Cabinet Medical valenciennes
CH Aix
hopital privé de bois bernard
Clinique La Croix du Sud
University Hospital, Bordeaux
Hopital Forcilles
Hopital d'instructions des armées
Hôpital Européen Marseille
Rennes University Hospital
Clinique Saint Augustin
Delafontaine Hospital
Centre Hospitalier Universitaire de Saint Etienne
Centre Hospitalier de Troyes
Centre Hospitalier le Mans
University Hospital, Clermont-Ferrand
University Hospital, Tours
Centre Hospitalier Universitaire, Amiens
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adults, older than 18 * SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in nasopharyngeal swab in patients who are evaluated by a pneumologist 5 to 7 months after their Covid-19 disease
Exclusion criteria
* patients for whom follow-up would be difficult owing to psychotic disorder * dementia * patients who have declined to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| desaturation during the 6 min walk test | at 5 months |
| Variation of vital capacity at 5 months after Covid-19 episode | at 5 months |
| Variation of vital capacity at 7 months after Covid-19 episode | at 7 months |
| DLCO alteration at 5 months after Covid-19 episode | at 5 months |
| DLCO alteration at 7 months after Covid-19 episode | at 7 months |
Secondary
| Measure | Time frame |
|---|---|
| Variation of VC spirometry parameters | at 5 months |
| Variation of FVC spirometry parameters | at 5 months |
| Variation of DLCO spirometry parameters | at 5 months |
| Variation of FEV1 spirometry parameters | at 5 months |
Countries
France
Outcome results
None listed